Cargando…

Immunologic adverse reactions of β-blockers and the skin

β-Blockers are a widely utilised class of medication. They have been in use for a variety of systemic disorders including hypertension, heart failure and intention tremors. Their use in dermatology has garnered growing interest with the discovery of their therapeutic effects in the treatment of haem...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatu, Alin Laurentiu, Elisei, Alina Mihaela, Chioncel, Valentin, Miulescu, Magdalena, Nwabudike, Lawrence Chukwudi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639944/
https://www.ncbi.nlm.nih.gov/pubmed/31384329
http://dx.doi.org/10.3892/etm.2019.7504
_version_ 1783436562019647488
author Tatu, Alin Laurentiu
Elisei, Alina Mihaela
Chioncel, Valentin
Miulescu, Magdalena
Nwabudike, Lawrence Chukwudi
author_facet Tatu, Alin Laurentiu
Elisei, Alina Mihaela
Chioncel, Valentin
Miulescu, Magdalena
Nwabudike, Lawrence Chukwudi
author_sort Tatu, Alin Laurentiu
collection PubMed
description β-Blockers are a widely utilised class of medication. They have been in use for a variety of systemic disorders including hypertension, heart failure and intention tremors. Their use in dermatology has garnered growing interest with the discovery of their therapeutic effects in the treatment of haemangiomas, their potential positive effects in wound healing, Kaposi sarcoma, melanoma and pyogenic granuloma, and, more recently, pemphigus. Since β-blockers are deployed in a variety of disorders, which have cutaneous co-morbidities such as psoriasis, their pertinence to dermatologists cannot be overstated. Likewise, β-blockers, like any other drug category, carry risks of side effects, some of which are dermatologic. These include triggering and exacerbation of psoriasis, psoriatic and rheumatoid arthritis, anaphylaxis, contact dermatitis, occupational contact dermatitis, Raynaud's disease, alopecia, lichen planus-like drug eruption, hyperhydrosis and vitiligo. While recent articles have focussed on the positive uses of β-blockers, it may also be wise to call our attention to the potential dermatologic adverse effects that may follow β-blocker use, as well as possible therapeutic approaches to these. This short review will focus on those dermatoses resulting from β-blocker use, which have an immunologic basis.
format Online
Article
Text
id pubmed-6639944
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-66399442019-08-05 Immunologic adverse reactions of β-blockers and the skin Tatu, Alin Laurentiu Elisei, Alina Mihaela Chioncel, Valentin Miulescu, Magdalena Nwabudike, Lawrence Chukwudi Exp Ther Med Review β-Blockers are a widely utilised class of medication. They have been in use for a variety of systemic disorders including hypertension, heart failure and intention tremors. Their use in dermatology has garnered growing interest with the discovery of their therapeutic effects in the treatment of haemangiomas, their potential positive effects in wound healing, Kaposi sarcoma, melanoma and pyogenic granuloma, and, more recently, pemphigus. Since β-blockers are deployed in a variety of disorders, which have cutaneous co-morbidities such as psoriasis, their pertinence to dermatologists cannot be overstated. Likewise, β-blockers, like any other drug category, carry risks of side effects, some of which are dermatologic. These include triggering and exacerbation of psoriasis, psoriatic and rheumatoid arthritis, anaphylaxis, contact dermatitis, occupational contact dermatitis, Raynaud's disease, alopecia, lichen planus-like drug eruption, hyperhydrosis and vitiligo. While recent articles have focussed on the positive uses of β-blockers, it may also be wise to call our attention to the potential dermatologic adverse effects that may follow β-blocker use, as well as possible therapeutic approaches to these. This short review will focus on those dermatoses resulting from β-blocker use, which have an immunologic basis. D.A. Spandidos 2019-08 2019-04-18 /pmc/articles/PMC6639944/ /pubmed/31384329 http://dx.doi.org/10.3892/etm.2019.7504 Text en Copyright: © Tatu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Tatu, Alin Laurentiu
Elisei, Alina Mihaela
Chioncel, Valentin
Miulescu, Magdalena
Nwabudike, Lawrence Chukwudi
Immunologic adverse reactions of β-blockers and the skin
title Immunologic adverse reactions of β-blockers and the skin
title_full Immunologic adverse reactions of β-blockers and the skin
title_fullStr Immunologic adverse reactions of β-blockers and the skin
title_full_unstemmed Immunologic adverse reactions of β-blockers and the skin
title_short Immunologic adverse reactions of β-blockers and the skin
title_sort immunologic adverse reactions of β-blockers and the skin
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639944/
https://www.ncbi.nlm.nih.gov/pubmed/31384329
http://dx.doi.org/10.3892/etm.2019.7504
work_keys_str_mv AT tatualinlaurentiu immunologicadversereactionsofbblockersandtheskin
AT eliseialinamihaela immunologicadversereactionsofbblockersandtheskin
AT chioncelvalentin immunologicadversereactionsofbblockersandtheskin
AT miulescumagdalena immunologicadversereactionsofbblockersandtheskin
AT nwabudikelawrencechukwudi immunologicadversereactionsofbblockersandtheskin